MA
NTGN

MYDA Advisors’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

MYDA Advisors’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-155,000
Closed -$267K – 183
2019
Q3 		$267K Buy
+155,000
New +$472K 0.12% 84

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors's NTGN Position: Q4 2019 in Review

MYDA Advisors sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q4 2019, closing a stake of 155,000 shares — an estimated $267K sold.

MYDA Advisors first reported a position in NTGN in Q3 2019 and held it in 1 quarter. The position peaked at $267K in Q3 2019. 46 funds tracked by Wall St. Rank hold NTGN as of Q4 2019.

  • MYDA Advisors reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • MYDA Advisors sold 155,000 Neon Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $267K.
  • MYDA Advisors first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • MYDA Advisors's Neon Therapeutics, Inc. Common Stock position peaked at $267K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q4 2019.

Based on MYDA Advisors's 13F filing for Q4 2019, filed 13 Feb 2020.